💊 Sosei continues Big Pharma alliances; WTO continues deferring decisions; China continues Covid transition

#240 | Whales make everything better

Hello, and welcome back for a brand new season of end-of-the-year Kables. 

Eli Lilly is partnering with Sosei Heptares to develop GPCR modulators for diabetes and metabolic diseases with a $37 million upfront payment. This is Lilly's second major announcement of December, after its tie-up with Egypt's EVA Pharma for cheaper insulin in LMICs. Sosei, meanw…